Antibiotic Treatment for Ochrobactrum Infection
For Ochrobactrum anthropi infections, treat with either a fluoroquinolone (ciprofloxacin or levofloxacin) or trimethoprim-sulfamethoxazole as first-line therapy, with carbapenems (imipenem or meropenem) or cefepime reserved for severe infections requiring intravenous therapy.
Antimicrobial Susceptibility Profile
Ochrobactrum anthropi demonstrates a characteristic resistance pattern that is critical for treatment selection:
- Highly resistant to beta-lactam antibiotics including ampicillin, cephalothin, cefonicid, amoxicillin-clavulanate, piperacillin, aztreonam, and ceftazidime 1, 2
- Highly susceptible to fluoroquinolones (ciprofloxacin 85.7-100%, levofloxacin 100%) 3, 1
- Highly susceptible to trimethoprim-sulfamethoxazole (85.7-97.1%) 3, 1
- Susceptible to carbapenems (imipenem 85.7%) and aminoglycosides (gentamicin, amikacin) 3, 2
- Variable susceptibility to third-generation cephalosporins (ceftriaxone, cefotaxime, cefoperazone show better activity than other cephalosporins) 2
Recommended Treatment Regimens
For Mild to Moderate Infections (Oral Therapy)
- Ciprofloxacin 500-750 mg orally twice daily 4, 1
- Trimethoprim-sulfamethoxazole (cotrimoxazole) at standard dosing 4, 1
For Severe Infections or Bacteremia (Intravenous Therapy)
- Cefepime 2 g IV every 8-12 hours for 15 days, followed by oral cotrimoxazole for 2 weeks 4
- Imipenem-cilastatin 500 mg IV every 6 hours 3, 2
- Ciprofloxacin 400 mg IV every 12 hours 3
- Ceftriaxone or cefotaxime as monotherapy (demonstrated good clinical response) 2
Critical Management Considerations
Catheter-Related Infections
Catheter removal is essential for recurrent or persistent Ochrobactrum bacteremia 3. All patients with O. anthropi bloodstream infections in reported series had indwelling catheters, though the organism can cause infection in patients without catheters 3, 2. While some low-virulence infections have been cured without catheter removal 5, recurrent infections mandate removal 3.
Surgical Debridement
For musculoskeletal infections, comprehensive surgical debridement combined with implant removal (if present) plus intravenous antibiotics is required for successful eradication 6. A case of hand infection required two surgical debridements before control was achieved, despite appropriate antibiotics 4.
Duration of Therapy
- Bacteremia: 10-14 days of appropriate antimicrobial therapy 3, 2
- Soft tissue/bone infections: 15 days IV therapy followed by 2 weeks oral therapy 4
- Recurrent infections: Extended therapy may be necessary 3
Clinical Context
Ochrobactrum anthropi is an opportunistic pathogen of relatively low virulence that can cause clinically significant infections in both immunocompromised and immunocompetent hosts 2, 7. The organism has an affinity for aquatic environments and indwelling plastic devices 7. Most infections present with fever (100% of cases) and may be community-acquired (67% in one series) or nosocomial 3, 2.
Common Pitfalls to Avoid
- Do not rely on empiric beta-lactam therapy (ampicillin, most cephalosporins, piperacillin-tazobactam) as O. anthropi shows intrinsic resistance to these agents 1, 2
- Do not assume catheter retention is adequate for persistent or recurrent bacteremia—removal is essential 3
- Do not use biochemical identification systems alone as they are unreliable for differentiating Ochrobactrum from Brucella species 1
- Do not undertreated soft tissue infections with antibiotics alone—surgical debridement is often necessary for source control 4, 6